Company Filing History:
Years Active: 2008
Title: Abjiheet Nag: Innovator in Amino Acid Derivatives
Introduction
Abjiheet Nag is a prominent inventor based in Fremont, CA, known for his significant contributions to the field of pharmaceuticals. He has been instrumental in developing novel compounds that address various health issues, particularly those related to inflammation and metabolic disorders. With a total of 2 patents, his work has the potential to impact the treatment of several medical conditions.
Latest Patents
Abjiheet Nag's latest patents include innovative hydroxamic acid-containing amino acid derivatives. These derivatives are designed to be useful in the treatment of inflammation, inflammatory and immunological diseases. They also play a role in lowering blood glucose, serum insulin, free fatty acids, cholesterol, and triglyceride levels, making them valuable for the treatment or prophylaxis of metabolic disorders. Another significant patent involves derivatives of amino acids aimed at managing obesity and related disorders. These novel amino acid derivatives are effective in lowering blood glucose levels in hyperglycemic disorders and addressing issues such as body weight gain and elevated lipid levels.
Career Highlights
Abjiheet Nag is currently associated with Bexel Pharmaceuticals, Inc., where he continues to innovate and develop new therapeutic solutions. His work is characterized by a strong focus on addressing critical health challenges through scientific research and development.
Collaborations
Abjiheet collaborates with notable colleagues in his field, including Debendranath Dey and Partha Neogi. Their combined expertise contributes to the advancement of pharmaceutical innovations.
Conclusion
Abjiheet Nag's contributions to the field of amino acid derivatives highlight his commitment to improving health outcomes through innovative research. His patents reflect a deep understanding of the complexities of metabolic and inflammatory diseases, positioning him as a key figure in pharmaceutical innovation.